SUMMARY To evaluate whether the increase in serum transcobalamin I, seen in patients with carcinoma, is caused by synthesis ofR-binder to tumour cells, the distribution ofvitamin BU2 R-binder in 125 malignant growths of the digestive tract was studied. Positive staining for R-binder with immunoperoxidase was observed in 85 (70%) carcinomas. Positive staining for R-binder was observed in all four cholangiocarcinomas studied, but was absent in nine hepatocellular carcinomas.
An increased concentration of serum transcobalamin I, a member of vitamin B12 binding proteins called Rbinder, is found in patients with myeloproliferative diseases.'2 Similar increases in patients with carcinoma have also been noted, and it has been speculated that the increase was caused by the synthesis of Rbinder in tumour cells."'2 Using an immunoperoxidase technique, we examined whether R-binder is detectable in various carcinomas of the digestive tract.
Material and methods
One hundred and twenty two carcinomas and three carcinoid tumours of the digestive tract were selected from the surgical pathology files of Kyoto University Hospital comprising: four squamous cell carcinomas of the oesophagus; 47 adenocarcinomas of the stomach; 21 adenocarcinomas and three carcinoid tumours of the colon; 24 carcinomas of the pancreas; 13 adenocarcinomas of the biliary tract; four cholangiocarcinomas; and nine hepatocellular carcinomas. Formalin fixed, paraffin embedded tissue blocks were available in all cases. Newly cut 4 gm thick sections were used for the study.
Immunostaining was performed using the indirect peroxidase labelled antibody technique as described previously. ' stomach, colon, pancreas and biliary tract (including cholangiocarcinomas), R-binder was detected in 65% to 90% of each organ, whereas none of the squamous cell carcinomas of the oesophagus or hepatocellular carcinomas showed positive staining for R-binder. In most of the well or moderately differentiated adenocarcinomas there was luminal staining of tumour glands and staining of the secretory material within lumens (figs 1 and 2). Cytoplasmic staining was also found in some cases (fig 3) . In poorly differentiated or mucin producing carcinomas R-binder was detected in the cytoplasm or mucin of some tumour cells with varying degrees of intensity (fig 4) . No significant correlation was observed between the incidence of Rbinder expression and tumour differentiation in carcinomas of the stomach, colon, and pancreas. In biliary tract carcinomas, however, the incidence of Rbinder expression was reduced with progressive dedifferentiation.
Discussion
R-binder, an immunologically identical vitamin B,2 binding protein, occurs in various body fluids, granulocytes, and serum. We previously examined the distribution of R-binder in the normal digestive system using an immunoperoxidase technique'3 and showed that R-binder was present in the epithelia of the bile ducts, gallbladder, pancreatic ducts, large and small intestine, and in the gastric mucosa with intestinal metaplasia. In this study we have shown that Rbinder was present not only in normal epithelia of the digestive tract but in carcinomas of the various digestive organs. It has been reported that an increased concentration of serum R-binder-that is, TCI, is occasionally found in patients with carcinoma. Waxman and Gilbert reported a high increase in serum vitamin B12 binding protein in some patients with hepatocellular carcinoma. 4 Carmel et al indicated that eight of 139 patients with non-haematological malignant disease showed high TCI concentrations.9 Sheppard et al observed that the tumour tissues of a patient with disseminated carcinoma of unknown origin, whose serum TCI was very high, contained considerably higher concentration of R-binder than normal tissues.'2 These findings suggest that the increase in serum TCI in patients with carcinoma is due to the synthesis of R-binder by tumour cells. The results of this study provide additional evidence that R-binder is produced in carcinoma cells.
The incidence ofcarcinomas containing R-binder in this series was much higher than that of the cases with a high concentration ofserum TCI reported by Carmel et al.9 This discrepancy may be because extensive malignant disease and a large number of tumour cells are needed before an increase in serum TCI concentration occurs. Indeed, almost all cases with high serum TCI had generalised metastases, especially in the liver.38 9'2 The increase in serum TCI in patients with carcinoma may have been caused by increased production of R-binder in the tumour cells and by decreased degradation in the liver.38 92 African blacks with hepatocellular carcinoma.'9 Thus hepatocellular carcinoma producing R-binder seems to be uncommon. Our present results on liver tumours suggest that R-binder detection in liver tumours may be of some value in differentiating cholangiocarcinoma from hepatocellular carcinoma except for the fibrolamellar variant.
In this study we also investigated whether there was an association between R-binder expression and the differentiation ofcarcinomas, but we could not show a clear association, except for the correlation between the incidence of R-binder expression and differentiation of the biliary tract carcinomas; not only well differentiated carcinomas but poorly differentiated carcinomas in the stomach, colon, and pancreas showed a high incidence of R-binder positivity. Moreover, staining intensity did not correlate with tumour differentiation. We could not find any association between R-binder and a particular histological type of carcinoma.
